Long Trader
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GREAT PR GO BLRX
midastouch017
If there is any way I can help please let me know.
midastouch017
Are you okay. Am following situation all day from here. Stay safe!!!!!!!!
midastouch017
woke up to find PRZO doubled my money and I sold out. Will take 1/2 of my profit to buy more BLRX and then wait for Przo to pull back and then buy back in. The sun is shining this morning.
"midastouch017"
So what are your thoughts with this dropping like a lead balloon? I bought a few more thousand this morning in the $1.30s . There is no bad news so it seem the shorts are on the loose at this point. I am still very profitable and if they take it to a buck I will probably go for another 5000 and then sit on it till it goes through at least 3 quarterly reports. I wish every short had a family member suffering from this deadly problem and then just maybe they would leave this little company alone. YES I AM A NASTY PERSON WHEN SOMEONE OR GROUP MESSES WITH A COMPANY THAT IS TRYING TO SAVE MILLIONS OF PEOPLES LIVES and of course my money.
Exhibit 1
FOR IMMEDIATE RELEASE
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
- 6 of 11 Patients in the Pilot Phase Experienced a Partial Response, with 4 Confirmed;
One Patient Experienced Resolution of the Hepatic Metastatic Lesion -
- Data Presented at AACR Special Conference on Pancreatic Cancer -
- Multi-Center, Randomized Phase 2 Study Currently Enrolling -
TEL AVIV, Israel, September 28, 2023 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced encouraging data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination clinical trial evaluating the company’s CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
The data were published in an online abstract as part of the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023. An oral presentation of the data will take place later today, September 28, 2023.
The pilot phase of the Phase 2 study enrolled 11 patients with metastatic pancreatic cancer. As of May 2023, 6 patients (55%) experienced a partial response (PR) of which 4 (36%) were confirmed PRs with one patient experiencing resolution of the hepatic (liver) metastatic lesion. Three patients (27%) experienced stable disease, resulting in a disease control rate of 82%. These findings compare favorably to historic partial response and disease control rates of 23% and 48%, respectively, reported with the current standard of care, the chemotherapy combination gemcitabine and nab-paclitaxel.
“These initial data from the pilot phase of this ongoing Phase 2 study give us hope that motixafortide could potentially serve as the backbone of a new treatment regimen for PDAC, which is among the most difficult cancers to treat,” said Philip Serlin, Chief Executive Officer of BioLineRx Ltd. “We are deeply committed to this important collaboration with Columbia University investigators and eagerly look forward to the data from the randomized phase of the trial.”
Based on these pilot data, earlier this year, the CheMo4METPANC Phase 2 trial was amended to become a randomized study, with planned enrollment increasing from 30 to 102 patients. The trial, sponsored by Columbia University, is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies. A poster of the amended clinical trial design was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago, Illinois (see abstract).
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and is expected to be the second leading cause of cancer-related death in the U.S. by 2023. Because it is typically diagnosed at later stages, greater than 80 percent of pancreatic cancer is inoperable. Most pancreatic cancer is incurable and unfortunately newer immunotherapy approaches, while beneficial against other solid tumor types, have had limited efficacy in pancreatic cancer due to immunosuppressive pathways.
An earlier single-arm, Phase 2a clinical trial (COMBAT/KEYNOTE-202) and pre-clinical studies evaluating motixafortide in combination with PD-1 immunotherapies and chemotherapies in PDAC have been promising, suggesting the ability of motixafortide to support an immune response.
__________________________________
Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
Westin Copley Place, Boston Massachusetts
Plenary Session Details
Title:
CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma
Presenter:
Gulam A. Manji, MD, PhD, Columbia University Irving Medical Center/New York Presbyterian, New York, N.Y.
Session:
Plenary Session 3: Clinical Updates
Date:
Thursday, September 28, 2023
Time:
2:30-4:40 pm EDT
About CheMo4METPANC Phase 2 Clinical Trial
The multi-center CheMo4METPANC Phase 2 clinical trial is a randomized, investigator-initiated clinical trial in first line metastatic pancreatic cancer. Sponsored by Columbia University, the study is evaluating the combination of CXCR4 inhibitor motixafortide, PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel, alone in 102 patients. The trial’s primary endpoint is progression free survival (PFS). Secondary objectives include safety, response rate, disease control rate, duration of clinical benefit and overall survival.
About Pancreatic Cancer
Pancreatic cancer has a low rate of early diagnosis and a poor prognosis. In the United States in 2023, an estimated 64,000 adults will be diagnosed with the disease, which accounts for approximately 3% of all cancers in the U.S. and about 7% of all cancer deaths. Worldwide, an estimated 496,000 people were diagnosed with the disease in 2020. In the U.S., if the cancer is detected at an early stage when surgical removal of the tumor is possible, the 5-year relative survival rate is 44%. About 12% of people are initially diagnosed at this stage. If the cancer has spread to surrounding tissues or organs, the 5-year relative survival rate is 15%. For the 52% of patients who are initially diagnosed with metastatic cancer, the 5-year relative survival rate is 3%.1 In particular, hepatic (liver) metastases are a critical risk factor driving poor prognoses for patients with metastatic PDAC. These data highlight the need for the development of new therapeutic options.
About Motixafortide in Cancer Immunotherapy
Motixafortide inhibits CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including pancreatic ductal adenocarcinoma (PDAC). Motixafortide leverages the expression of the CXCR4 receptor on different immune cells and potentiates the immune system against the tumor. Among CXCR4-expressing immune cells, some exhibit anti-tumoral activity, such as effector T cells and some exhibit pro-tumoral activity and support tumor growth. By blocking the CXCR4 receptor, motixafortide was shown in a Phase 2 study in pancreatic cancer patients to enhance anti-tumoral activity and to ameliorate the pro-tumoral activities by modulating the effector/suppressor cell ratio towards a proinflammatory profile.
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company’s first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for?autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.
Learn more about who we are, what we do, and how we do it at?www.biolinerx.com, or on?Twitter?and?LinkedIn.?
Forward Looking Statement
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, the potential benefits of APHEXDA, the timing and execution of the launch of APHEXDA and the plans and objectives of management for future operations and expectations and commercial potential of motixafortide, as well as its potential investigational uses. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; statements as to the impact of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 22, 2023. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.
Contacts:
United States
John Lacey
BioLineRx
Something is wrong here. Hope we don't have another GMDA. The PR this morning was at best very mundane. The announcement should have had lights and bells and whistles around it. The people getting the word out are terrible as they are not good at flaring the word The company needs to understand we kept them alive when things were not so positive. Get off your asses and get the word out. There is no one more positive on this company. but don't screw it up
What is wrong with GMDA ???? Glad I cashed in a while back (still at a profit) and bought more BLRX.
adamp is a short don't waste your time with him just block him out. He rolls out when things look good for us longs and his shorts FLAME UP.
Great finish to a great day. Hopefully this will carry through to the end of the month where new momentum will care us even further. It looks like shorts are in trouble. I called my two brokerage houses that hold shares of BLRX for me and told them under no circumstances are they to use my shares in any way until I tell them to and told them I will not sell under $150/share or I tell them otherwise.
HC Wainwright& Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $19 to $21.
HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21
6:11 am ET September 15, 2023 (Benzinga
adamp
Correction to my previous post to you. I have taken from my gain on BLRX $62,000 to put aside to buy instead to lease my a 2024 Tesla model 3. I have given my 5 grand children $5000 each to pay for books when they are ready for college and still have just under 100,000 shares left that will make my wife and me very comfortable along with her pention from teaching for 35 years and my reserves from running my own business plus both our social security. Just so you understand I have series 6 and 66 licenses from when I studied the market and studied for the series 7 license to become a broker but never took the test. I decided I could not be a broker and have to take money from people I knew could not afford to lose those dollars. You see son I am some 35 years older then you and seem to have a lot more wisdom. ENOUGH SAID. Oh and last point I have been been in the market for 53 years and have spent only the markets money the last 40 years.
Son learn to treat people the same as you want to be treated IT WORKS!!!!
One day bad showing and you throw in the towel on them. What has changed. just wait for the string of good financial news and you will be crying in your glass of water,What a weakie you have to learn how to play this market. It always is the case buy up to the news then sell on the news. Let's see what the end of the week looks like. Oh you sold out sucks to be you. Study the stock so you can understand the company. Better yet understand the market or don't play where you don't belong.
adamp
Let's take a look at what BLRX has done for me so far. So far I have put away $62,000 thanks to this company for re-leasing another Tesla model 3 in 2024. much more shares still under the wing . So how did your short position do
Bought another 5000 this morning
Congrats to BioLineRx we longs love you!!!!!!!!!!!!!!
Well this is it.Like the eagles game it will come down to the last play at 7AM tomorrow morning.
BEST OF LUCK TO ALL LONGS
Would it surprise you if the FDA doesn't meet their required date to report. Hell they only had months to get this done, Our government sucks but to tell the truth it still is the best around and I have traveled enough of this world to say this. If you take the time to study the FDA in my opinion you will learn that they too are a corrupt part of our government. GOD help us to find the people to go into our government and clean up the mess.
This is strictly my opinion and should be taken that way
STOCKTWITS posters VERY POSITIVE
I will stick with $3.75 close Monday if FDA is favorable.
$3.75 end of regular trading Friday if FDA announces positive.
I guess we need to check back at 3:59 and 59 seconds.
Answer to your question is you probably will not hear from me for a month as I go back to Africa for a longer safari. It was a past dream that came true for me once. I am a nature lover. Especially animals. Seeing the Big 5 in person exploded my head. But I grew a new one (HA HA!!!)
I was not thinking of a dis-approval but possibly a temp hold for additional info. Trust me I am not trying to POOP on my parade. Just gun shy on a share price drop like we had to face earlier
I would like to believe that but in this day and age I cannot believe that. I am sorry to have to believe that way but just look at our own government. Even they cannot keep a secret.
SO WOULD I. I don't publically give out my figures anymore. I have shares in my name,kids names and wife's name as well as company name for legal reasons.
SO WOULD I. I don't publically give out my figures anymore. I have shares in my name,kids names and wife's name as well as company name for legal reasons.
Also locks out future profits. So it swings both ways. If you are in this stock as a long you have to have BALLS.
Okay did someone close to the company leak some bad news$ I cannot find anything on the internet that would cause a drop like this. People hold your shares for now this is not a time to sell right before the announcement. If and it should go our way you will be kicking yourself in the ass (that is if you can turn your foot around to do so). DO NOT LET THE MARKETMAKERS STEAL YOUR SHARES. This of course is my opinion and should not be taken in any decision you might make.
Nothing like a drop in share price to get the blood flowing . I think it may be the market makers trying to scare up the weak to sell so they (market makers) have some shares to sell.
ZACK in a early report on BLRX felt that the approval would boost the share price into the low $4's. My personal thoughts on ZACK is that they are usually WRONG. But they feel as sales and revenues start to show up the stock could bubble into double digits. FROM THEIR MOUTH TO GOD'S ears.
As long as Tuesday is positive who knows where we will go up to on the 8th or 11th.
BEST TO ALL US LONGS
9/01/2023 Closing 3,264,324. Shares traded Closing $2.02/share breaks yesterday's close.
YIPPE !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!/b]
We have set another volume record 3,060,000 with 7 minutes still to go before close.
Some of today's numbers from Investors Hub
Up at 4PM Buy Volume 1,529,884
Sell Volume 1,054,035
? Volume 452,551 Have no idea what ? volume is
Total trades 8,422
TODAY WAS THE HIGHEST VOLUME DAY SO FAR THIS YEAR
Looks like market makers are trying to hold it back by slapping the bid with 100 share trades after it tries to move up again. Just wait for explosion day Sept 9th, 2023. Mark that date down in your memory bank.
Can't wait for Sept. 9th MOTHER GOOSE is laying on my GOLDEN EGGS. GMDA----BLRX (more BLRX)
bought a 10 spot of CGEN at the 4PM close today they have a product they are partnered with Aztra Zeneca and they are getting payments at this point that if it meets certain criterias could bring in up to $200 million. They have so far gotten 15 million. Another Israeli company that could make me a billion dollars. If it did I would probably fall over and die. Looks like PLUR might have something they had a announcement today that COULD be prommising. If all my COULD BE PROMISSING would come through I could help Biden pay of his trillion dollar spending sprees. In my opinion it must be great to be dumb and president at the same time. Looks like USA is heading for a civil war. Hope they hold off till I take a dirt nap.
Bought almost 8000 shares today have very high hopes for this stock.